Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast

Addex Therapeutics (OTCMKTS:ADDXF) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Addex Therapeutics and Kiora Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	0	0	0	0	0.00
Kiora Pharmaceuticals	0	0	1	1	3.50

Kiora Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 176.24%. Given Kiora Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Addex Therapeutics.

Institutional and Insider Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.9% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Addex Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500.

Profitability

This table compares Addex Therapeutics and Kiora Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	N/A	N/A
Kiora Pharmaceuticals	N/A	21.32%	16.39%

Valuation and Earnings

This table compares Addex Therapeutics and Kiora Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals	$16.00 million	0.68	-$12.51 million	N/A	N/A

Addex Therapeutics has higher earnings, but lower revenue than Kiora Pharmaceuticals.

Summary

Kiora Pharmaceuticals beats Addex Therapeutics on 9 of the 10 factors compared between the two stocks.

About Addex Therapeutics

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.